EGFR and non-small cell lung carcinoma: On the other hand the FLAURA study compared the efficacy of osimertinib monotherapy with the efficacy of standard of care (SoC), i.e., erlotinib or gefitinib therapy in patients with advanced NSCLC with frequent EGFR mutations (deletions in exon 19 or L858R substitution in exon 21) indicating the applicability of osimertinib in the first line of treatment in monotherapy [11].